Semaglutide Reduces MACE, Death in Participants With CVD, Overweight/Obesity, and Impaired Kidney Function - Medscape Semaglutide 減少心血管事件(MACE)、死亡率,適用於有心血管疾病(CVD)、超重/肥胖及腎功能受損的參與者。
Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial.
2型糖尿病中慢性腎病嚴重程度對semaglutide心血管結果的影響:FLOW試驗。
Eur Heart J 2024-08-30
Cardiovascular event reduction among a US population eligible for semaglutide per the SELECT trial.
根據 SELECT 試驗,符合使用 semaglutide 的美國人群心血管事件減少情況。
Am Heart J 2024-08-25
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.
Semaglutide 與肥胖及心臟衰竭患者的心血管結果:SELECT 試驗的預先指定分析。
Lancet 2024-08-24
Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT.
Semaglutide在SELECT研究中對基線HbA1c和HbA1c變化的超重或肥胖但無糖尿病人群的心血管結果。
Diabetes Care 2024-06-22
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.
Semaglutide在肥胖和心血管疾病中的SELECT試驗中的長期腎臨床結果。
Nat Med 2024-05-25
The impact of weekly semaglutide, a glucagon-like peptide-1 agonist, on kidney outcomes in adults with type 2 diabetes mellitus.
每週一次的血糖素樣肽-1激動劑semaglutide對2型糖尿病成人腎臟結果的影響。
J Family Med Prim Care 2024-04-25
In adults with overweight or obesity and CVD, but without diabetes, semaglutide reduced MACE at a mean 40 mo.
在超重或肥胖且患心血管疾病但沒有糖尿病的成年人中,Semaglutide 在平均 40 個月內降低了主要心血管事件(MACE)。
Ann Intern Med 2024-03-20
Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis.
Semaglutide對基線腎功能參數不同的2型糖尿病患者及高心血管疾病風險者主要不良心血管事件的影響:SUSTAIN 6和PIONEER 6事後合併分析。
Cardiovasc Diabetol 2023-11-21